IL313248A - Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases - Google Patents

Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases

Info

Publication number: IL313248A
Authority: IL; Israel
Prior art keywords: formulation; component; weight; oil; amount
Prior art date: 2021-12-03

Application number

IL313248A

Other languages

English (en)

Hebrew (he)

Inventor

Marc Brown

Vanessa Cofre

Charles Evans

James Fidge

Florencia Guidali

Tecashanell Mcintosh

Naresh Modepalli

Trupti Sheth

Original Assignee

Marc Brown

Vanessa Cofre

Charles Evans

James Fidge

Florencia Guidali

Incyte Corp

Tecashanell Mcintosh

Naresh Modepalli

Trupti Sheth

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-12-03

Filing date

2022-12-04

Publication date

2024-08-01

2021-12-03 Priority claimed from US17/541,601 external-priority patent/US12005067B2/en

2022-12-04 Application filed by Marc Brown, Vanessa Cofre, Charles Evans, James Fidge, Florencia Guidali, Incyte Corp, Tecashanell Mcintosh, Naresh Modepalli, Trupti Sheth filed Critical Marc Brown

2022-12-04 Priority claimed from PCT/US2022/080873 external-priority patent/WO2023102559A1/fr

2024-08-01 Publication of IL313248A publication Critical patent/IL313248A/en

Links

208000017520 skin disease Diseases 0.000 title claims description 83
239000012049 topical pharmaceutical composition Substances 0.000 title claims description 75
-1 PTZ amine Chemical class 0.000 title description 144
239000000203 mixture Substances 0.000 claims description 788
238000009472 formulation Methods 0.000 claims description 736
239000002904 solvent Substances 0.000 claims description 262
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 187
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 173
239000003921 oil Substances 0.000 claims description 153
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 120
239000003995 emulsifying agent Substances 0.000 claims description 115
150000001412 amines Chemical class 0.000 claims description 106
239000003002 pH adjusting agent Substances 0.000 claims description 98
150000003839 salts Chemical class 0.000 claims description 81
239000000546 pharmaceutical excipient Substances 0.000 claims description 78
239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 75
229960000215 ruxolitinib Drugs 0.000 claims description 75
HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 74
102100030703 Interleukin-22 Human genes 0.000 claims description 73
108010074109 interleukin-22 Proteins 0.000 claims description 73
230000001404 mediated effect Effects 0.000 claims description 65
239000007921 spray Substances 0.000 claims description 63
239000002585 base Substances 0.000 claims description 61
239000006071 cream Substances 0.000 claims description 60
239000003381 stabilizer Substances 0.000 claims description 60
239000006210 lotion Substances 0.000 claims description 56
102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 54
JFMWPOCYMYGEDM-XFULWGLBSA-N ruxolitinib phosphate Chemical compound OP(O)(O)=O.C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 JFMWPOCYMYGEDM-XFULWGLBSA-N 0.000 claims description 53
238000000034 method Methods 0.000 claims description 52
229960002539 ruxolitinib phosphate Drugs 0.000 claims description 52
239000000080 wetting agent Substances 0.000 claims description 52
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 51
239000003380 propellant Substances 0.000 claims description 51
229960004418 trolamine Drugs 0.000 claims description 51
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 50
239000003755 preservative agent Substances 0.000 claims description 46
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 45
230000001804 emulsifying effect Effects 0.000 claims description 43
239000003112 inhibitor Substances 0.000 claims description 43
239000006260 foam Substances 0.000 claims description 39
101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 38
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 36
239000002738 chelating agent Substances 0.000 claims description 35
201000004681 Psoriasis Diseases 0.000 claims description 34
239000012458 free base Substances 0.000 claims description 34
239000003795 chemical substances by application Substances 0.000 claims description 33
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 30
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 30
239000003349 gelling agent Substances 0.000 claims description 26
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 24
206010012438 Dermatitis atopic Diseases 0.000 claims description 19
201000008937 atopic dermatitis Diseases 0.000 claims description 19
230000002335 preservative effect Effects 0.000 claims description 18
101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 16
206010047642 Vitiligo Diseases 0.000 claims description 16
LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 claims description 15
229940043276 diisopropanolamine Drugs 0.000 claims description 15
206010021198 ichthyosis Diseases 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 15
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 15
230000000087 stabilizing effect Effects 0.000 claims description 15
206010012442 Dermatitis contact Diseases 0.000 claims description 14
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 14
208000010247 contact dermatitis Diseases 0.000 claims description 14
201000011486 lichen planus Diseases 0.000 claims description 14
201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 13
201000005962 mycosis fungoides Diseases 0.000 claims description 13
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 13
229910021529 ammonia Inorganic materials 0.000 claims description 12
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 12
229940043279 diisopropylamine Drugs 0.000 claims description 12
206010035116 pityriasis rubra pilaris Diseases 0.000 claims description 12
239000004094 surface-active agent Substances 0.000 claims description 11
208000002557 hidradenitis Diseases 0.000 claims description 10
201000007162 hidradenitis suppurativa Diseases 0.000 claims description 10
239000007764 o/w emulsion Substances 0.000 claims description 10
101150033466 Defb4 gene Proteins 0.000 claims description 9
239000003963 antioxidant agent Substances 0.000 claims description 9
208000007150 epidermolysis bullosa simplex Diseases 0.000 claims description 9
150000003512 tertiary amines Chemical group 0.000 claims description 9
206010033554 Palmoplantar keratoderma Diseases 0.000 claims description 8
208000033464 Reiter syndrome Diseases 0.000 claims description 8
241001303601 Rosacea Species 0.000 claims description 8
239000007983 Tris buffer Substances 0.000 claims description 8
230000003078 antioxidant effect Effects 0.000 claims description 8
239000003906 humectant Substances 0.000 claims description 8
201000008743 palmoplantar keratosis Diseases 0.000 claims description 8
208000002574 reactive arthritis Diseases 0.000 claims description 8
201000004700 rosacea Diseases 0.000 claims description 8
230000002195 synergetic effect Effects 0.000 claims description 8
239000002562 thickening agent Substances 0.000 claims description 8
201000004384 Alopecia Diseases 0.000 claims description 7
201000004624 Dermatitis Diseases 0.000 claims description 7
108050003558 Interleukin-17 Proteins 0.000 claims description 7
102000013691 Interleukin-17 Human genes 0.000 claims description 7
208000001052 Pachyonychia Congenita Diseases 0.000 claims description 7
231100000360 alopecia Toxicity 0.000 claims description 7
239000003623 enhancer Substances 0.000 claims description 7
239000003205 fragrance Substances 0.000 claims description 7
230000035515 penetration Effects 0.000 claims description 7
206010048905 steatocystoma multiplex Diseases 0.000 claims description 7
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
239000003086 colorant Substances 0.000 claims description 6
101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 5
102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 5
230000002500 effect on skin Effects 0.000 claims description 5
BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
208000002874 Acne Vulgaris Diseases 0.000 claims description 4
206010012504 Dermatophytosis Diseases 0.000 claims description 4
206010016654 Fibrosis Diseases 0.000 claims description 4
102100028314 Filaggrin Human genes 0.000 claims description 4
208000000185 Localized scleroderma Diseases 0.000 claims description 4
241001460074 Microsporum distortum Species 0.000 claims description 4
206010027982 Morphoea Diseases 0.000 claims description 4
208000007256 Nevus Diseases 0.000 claims description 4
208000002474 Tinea Diseases 0.000 claims description 4
206010000496 acne Diseases 0.000 claims description 4
230000004761 fibrosis Effects 0.000 claims description 4
HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 claims description 3
108010074328 Interferon-gamma Proteins 0.000 claims description 3
230000001363 autoimmune Effects 0.000 claims description 3
101710088660 Filaggrin Proteins 0.000 claims description 2
101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 2
101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 2
102000008070 Interferon-gamma Human genes 0.000 claims description 2
102000017761 Interleukin-33 Human genes 0.000 claims description 2
108010067003 Interleukin-33 Proteins 0.000 claims description 2
108090000978 Interleukin-4 Proteins 0.000 claims description 2
102000004388 Interleukin-4 Human genes 0.000 claims description 2
108010006035 Metalloproteases Proteins 0.000 claims description 2
102000005741 Metalloproteases Human genes 0.000 claims description 2
102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 2
102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims description 2
229960003130 interferon gamma Drugs 0.000 claims description 2
239000011159 matrix material Substances 0.000 claims description 2
102000042838 JAK family Human genes 0.000 claims 4
108091082332 JAK family Proteins 0.000 claims 4
235000019198 oils Nutrition 0.000 description 125
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 85
229920001223 polyethylene glycol Polymers 0.000 description 77
239000000126 substance Substances 0.000 description 76
239000002202 Polyethylene glycol Substances 0.000 description 61
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 57
235000019441 ethanol Nutrition 0.000 description 54
235000011187 glycerol Nutrition 0.000 description 54
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 48
239000000499 gel Substances 0.000 description 47
229920001983 poloxamer Polymers 0.000 description 45
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 41
235000014113 dietary fatty acids Nutrition 0.000 description 41
239000000194 fatty acid Substances 0.000 description 41
229930195729 fatty acid Natural products 0.000 description 41
108010024121 Janus Kinases Proteins 0.000 description 39
102000015617 Janus Kinases Human genes 0.000 description 39
150000004665 fatty acids Chemical class 0.000 description 38
239000012071 phase Substances 0.000 description 34
150000002191 fatty alcohols Chemical class 0.000 description 33
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 31
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
229960004063 propylene glycol Drugs 0.000 description 29
102100027998 Macrophage metalloelastase Human genes 0.000 description 28
235000013772 propylene glycol Nutrition 0.000 description 28
101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 27
229960000541 cetyl alcohol Drugs 0.000 description 26
150000001875 compounds Chemical class 0.000 description 25
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 24
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 24
229920000053 polysorbate 80 Polymers 0.000 description 24
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 22
201000010099 disease Diseases 0.000 description 22
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 22
229940068968 polysorbate 80 Drugs 0.000 description 22
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 22
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 21
229920001213 Polysorbate 20 Polymers 0.000 description 20
239000003814 drug Substances 0.000 description 20
229940079593 drug Drugs 0.000 description 20
229960005323 phenoxyethanol Drugs 0.000 description 20
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 20
229920003171 Poly (ethylene oxide) Polymers 0.000 description 19
239000004359 castor oil Substances 0.000 description 19
229950009789 cetomacrogol 1000 Drugs 0.000 description 19
229940056211 paraffin Drugs 0.000 description 19
239000012188 paraffin wax Substances 0.000 description 19
229940068977 polysorbate 20 Drugs 0.000 description 19
239000002253 acid Substances 0.000 description 18
150000002194 fatty esters Chemical class 0.000 description 18
229940075507 glyceryl monostearate Drugs 0.000 description 18
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 18
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 18
229940012831 stearyl alcohol Drugs 0.000 description 18
IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 17
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 17
229940082500 cetostearyl alcohol Drugs 0.000 description 17
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 17
229920000642 polymer Polymers 0.000 description 17
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 16
239000004166 Lanolin Substances 0.000 description 16
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
229940008099 dimethicone Drugs 0.000 description 16
239000004205 dimethyl polysiloxane Substances 0.000 description 16
235000013870 dimethyl polysiloxane Nutrition 0.000 description 16
239000008387 emulsifying waxe Substances 0.000 description 16
235000019388 lanolin Nutrition 0.000 description 16
229940039717 lanolin Drugs 0.000 description 16
238000010979 pH adjustment Methods 0.000 description 16
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 16
239000001993 wax Substances 0.000 description 16
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 15
HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 15
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 15
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 15
150000002195 fatty ethers Chemical class 0.000 description 15
239000004322 Butylated hydroxytoluene Substances 0.000 description 14
229940059904 light mineral oil Drugs 0.000 description 14
235000019271 petrolatum Nutrition 0.000 description 14
210000003491 skin Anatomy 0.000 description 14
239000000230 xanthan gum Substances 0.000 description 14
229920001285 xanthan gum Polymers 0.000 description 14
229940082509 xanthan gum Drugs 0.000 description 14
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 13
229940031098 ethanolamine Drugs 0.000 description 13
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 13
229920002545 silicone oil Polymers 0.000 description 13
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 12
235000010354 butylated hydroxytoluene Nutrition 0.000 description 12
229940095259 butylated hydroxytoluene Drugs 0.000 description 12
229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 12
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 12
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 12
229960002216 methylparaben Drugs 0.000 description 12
CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 11
235000019438 castor oil Nutrition 0.000 description 11
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 11
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 11
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 11
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 11
229960003415 propylparaben Drugs 0.000 description 11
239000003351 stiffener Substances 0.000 description 11
235000010493 xanthan gum Nutrition 0.000 description 11
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 10
239000008186 active pharmaceutical agent Substances 0.000 description 10
235000013871 bee wax Nutrition 0.000 description 10
229940092738 beeswax Drugs 0.000 description 10
239000012166 beeswax Substances 0.000 description 10
229920001577 copolymer Polymers 0.000 description 10
239000000839 emulsion Substances 0.000 description 10
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 10
239000007788 liquid Substances 0.000 description 10
229940057917 medium chain triglycerides Drugs 0.000 description 10
239000000243 solution Substances 0.000 description 10
150000003626 triacylglycerols Chemical class 0.000 description 10
239000004264 Petrolatum Substances 0.000 description 9
239000004203 carnauba wax Substances 0.000 description 9
235000013869 carnauba wax Nutrition 0.000 description 9
229940082483 carnauba wax Drugs 0.000 description 9
229940086555 cyclomethicone Drugs 0.000 description 9
229940066842 petrolatum Drugs 0.000 description 9
206010020751 Hypersensitivity Diseases 0.000 description 8
229910000147 aluminium phosphate Inorganic materials 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
235000012000 cholesterol Nutrition 0.000 description 8
229940110456 cocoa butter Drugs 0.000 description 8
235000019868 cocoa butter Nutrition 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 8
229940100460 peg-100 stearate Drugs 0.000 description 8
229960004838 phosphoric acid Drugs 0.000 description 8
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
235000019737 Animal fat Nutrition 0.000 description 7
239000004215 Carbon black (E152) Substances 0.000 description 7
229930182558 Sterol Natural products 0.000 description 7
239000004164 Wax ester Substances 0.000 description 7
208000026935 allergic disease Diseases 0.000 description 7
230000007815 allergy Effects 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
239000003974 emollient agent Substances 0.000 description 7
150000002148 esters Chemical class 0.000 description 7
229930195733 hydrocarbon Natural products 0.000 description 7
150000002430 hydrocarbons Chemical class 0.000 description 7
229910052500 inorganic mineral Inorganic materials 0.000 description 7
239000011707 mineral Substances 0.000 description 7
229920001992 poloxamer 407 Polymers 0.000 description 7
229940044476 poloxamer 407 Drugs 0.000 description 7
229920001296 polysiloxane Polymers 0.000 description 7
229920006395 saturated elastomer Polymers 0.000 description 7
150000003432 sterols Chemical class 0.000 description 7
235000003702 sterols Nutrition 0.000 description 7
150000005846 sugar alcohols Polymers 0.000 description 7
239000012178 vegetable wax Substances 0.000 description 7
235000019386 wax ester Nutrition 0.000 description 7
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 6
229920002669 Polyoxyl 20 Cetostearyl Ether Polymers 0.000 description 6
208000004631 alopecia areata Diseases 0.000 description 6
239000008346 aqueous phase Substances 0.000 description 6
238000012512 characterization method Methods 0.000 description 6
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
150000002398 hexadecan-1-ols Chemical class 0.000 description 6
125000006353 oxyethylene group Chemical group 0.000 description 6
239000000600 sorbitol Substances 0.000 description 6
LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 6
235000019871 vegetable fat Nutrition 0.000 description 6
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 5
JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 5
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 5
102000019034 Chemokines Human genes 0.000 description 5
108010012236 Chemokines Proteins 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
150000004676 glycans Chemical class 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
238000011068 loading method Methods 0.000 description 5
239000002736 nonionic surfactant Substances 0.000 description 5
230000008506 pathogenesis Effects 0.000 description 5
230000007170 pathology Effects 0.000 description 5
229920001282 polysaccharide Polymers 0.000 description 5
239000005017 polysaccharide Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 5
LGJWVXWQCTZSGC-XFULWGLBSA-N (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;sulfuric acid Chemical compound OS(O)(=O)=O.C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 LGJWVXWQCTZSGC-XFULWGLBSA-N 0.000 description 4
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 4
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
108010065637 Interleukin-23 Proteins 0.000 description 4
102000013264 Interleukin-23 Human genes 0.000 description 4
229940122245 Janus kinase inhibitor Drugs 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 4
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
229960000510 ammonia Drugs 0.000 description 4
208000037896 autoimmune cutaneous disease Diseases 0.000 description 4
239000000872 buffer Substances 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
229920003118 cationic copolymer Polymers 0.000 description 4
229940043237 diethanolamine Drugs 0.000 description 4
150000002170 ethers Chemical class 0.000 description 4
UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 4
208000029443 keratinization disease Diseases 0.000 description 4
239000011976 maleic acid Substances 0.000 description 4
XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 4
239000002480 mineral oil Substances 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
229960000502 poloxamer Drugs 0.000 description 4
239000000047 product Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
235000011069 sorbitan monooleate Nutrition 0.000 description 4
239000001593 sorbitan monooleate Substances 0.000 description 4
229940035049 sorbitan monooleate Drugs 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
229920000428 triblock copolymer Polymers 0.000 description 4
239000003871 white petrolatum Substances 0.000 description 4
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
CDOOAUSHHFGWSA-OWOJBTEDSA-N (e)-1,3,3,3-tetrafluoroprop-1-ene Chemical compound F\C=C\C(F)(F)F CDOOAUSHHFGWSA-OWOJBTEDSA-N 0.000 description 3
ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 3
229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 3
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 3
108010066325 Keratin-17 Proteins 0.000 description 3
239000005639 Lauric acid Substances 0.000 description 3
239000005642 Oleic acid Substances 0.000 description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
229920000604 Polyethylene Glycol 200 Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
229940075529 glyceryl stearate Drugs 0.000 description 3
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
239000003446 ligand Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
125000005702 oxyalkylene group Chemical group 0.000 description 3
150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
229920001515 polyalkylene glycol Polymers 0.000 description 3
239000008213 purified water Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 2
CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 2
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
229940044613 1-propanol Drugs 0.000 description 2
JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 2
IOAOAKDONABGPZ-UHFFFAOYSA-N 2-amino-2-ethylpropane-1,3-diol Chemical compound CCC(N)(CO)CO IOAOAKDONABGPZ-UHFFFAOYSA-N 0.000 description 2
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 2
229920003149 Eudragit® E 100 Polymers 0.000 description 2
229920003134 Eudragit® polymer Polymers 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
208000001913 Lamellar ichthyosis Diseases 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
201000009053 Neurodermatitis Diseases 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
229920002675 Polyoxyl Polymers 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
239000004147 Sorbitan trioleate Substances 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
201000002006 bullous congenital ichthyosiform erythroderma Diseases 0.000 description 2
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000000306 component Substances 0.000 description 2
239000012050 conventional carrier Substances 0.000 description 2
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
230000009266 disease activity Effects 0.000 description 2
NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
229940124274 edetate disodium Drugs 0.000 description 2
239000012636 effector Substances 0.000 description 2
208000033286 epidermolytic ichthyosis Diseases 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
229920000831 ionic polymer Polymers 0.000 description 2
230000003902 lesion Effects 0.000 description 2
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
229940055577 oleyl alcohol Drugs 0.000 description 2
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
239000003961 penetration enhancing agent Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
235000011007 phosphoric acid Nutrition 0.000 description 2
150000003016 phosphoric acids Chemical class 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229940113115 polyethylene glycol 200 Drugs 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
239000000473 propyl gallate Substances 0.000 description 2
235000010388 propyl gallate Nutrition 0.000 description 2
229940075579 propyl gallate Drugs 0.000 description 2
208000017940 prurigo nodularis Diseases 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000004044 response Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
229960004025 sodium salicylate Drugs 0.000 description 2
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
229940035044 sorbitan monolaurate Drugs 0.000 description 2
235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
239000001570 sorbitan monopalmitate Substances 0.000 description 2
229940031953 sorbitan monopalmitate Drugs 0.000 description 2
235000011076 sorbitan monostearate Nutrition 0.000 description 2
239000001587 sorbitan monostearate Substances 0.000 description 2
229940035048 sorbitan monostearate Drugs 0.000 description 2
235000019337 sorbitan trioleate Nutrition 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
235000011078 sorbitan tristearate Nutrition 0.000 description 2
239000001589 sorbitan tristearate Substances 0.000 description 2
229960004129 sorbitan tristearate Drugs 0.000 description 2
238000012430 stability testing Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
229940100611 topical cream Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000036572 transepidermal water loss Effects 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 description 1
IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
OOWQBDFWEXAXPB-IBGZPJMESA-N 1-O-hexadecyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](O)CO OOWQBDFWEXAXPB-IBGZPJMESA-N 0.000 description 1
229940114072 12-hydroxystearic acid Drugs 0.000 description 1
KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
CIHKVMHPDDJIIP-UHFFFAOYSA-N 2-methylperoxybenzoic acid Chemical compound COOC1=CC=CC=C1C(O)=O CIHKVMHPDDJIIP-UHFFFAOYSA-N 0.000 description 1
HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 description 1
HJVKLVGLKNGYGQ-UHFFFAOYSA-N 20-methylhenicosanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCCCCCC(O)=O HJVKLVGLKNGYGQ-UHFFFAOYSA-N 0.000 description 1
NRWMBHYHFFGEEC-MDZDMXLPSA-N 3-[(e)-octadec-9-enoxy]propane-1,2-diol Chemical compound CCCCCCCC\C=C\CCCCCCCCOCC(O)CO NRWMBHYHFFGEEC-MDZDMXLPSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000005151 Acquired ichthyosis Diseases 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
108700042778 Antimicrobial Peptides Proteins 0.000 description 1
102000044503 Antimicrobial Peptides Human genes 0.000 description 1
235000021357 Behenic acid Nutrition 0.000 description 1
DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000030060 Congenital non-bullous ichthyosiform erythroderma Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
101000869592 Daucus carota Major allergen Dau c 1 Proteins 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
208000031797 Harlequin ichthyosis Diseases 0.000 description 1
101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 1
101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 1
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
101000650136 Homo sapiens WAS/WASL-interacting protein family member 3 Proteins 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
206010021199 Ichthyosis acquired Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
108010019421 Janus Kinase 3 Proteins 0.000 description 1
229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
206010066295 Keratosis pilaris Diseases 0.000 description 1
229920002884 Laureth 4 Polymers 0.000 description 1
210000004322 M2 macrophage Anatomy 0.000 description 1
101710187853 Macrophage metalloelastase Proteins 0.000 description 1
229920003096 Methocel™ K100M Polymers 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010028703 Nail psoriasis Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
235000021319 Palmitoleic acid Nutrition 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
229920002596 Polyethylene Glycol 900 Polymers 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
206010037575 Pustular psoriasis Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
150000004935 Ruxolitinib derivatives Chemical class 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
101150043341 Socs3 gene Proteins 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 1
108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
210000004241 Th2 cell Anatomy 0.000 description 1
239000005844 Thymol Substances 0.000 description 1
108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
102000002689 Toll-like receptor Human genes 0.000 description 1
108020000411 Toll-like receptor Proteins 0.000 description 1
102100039390 Toll-like receptor 7 Human genes 0.000 description 1
102100033110 Toll-like receptor 8 Human genes 0.000 description 1
102100033117 Toll-like receptor 9 Human genes 0.000 description 1
102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
102100027539 WAS/WASL-interacting protein family member 3 Human genes 0.000 description 1
208000001001 X-linked ichthyosis Diseases 0.000 description 1
LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
230000001436 acantholytic effect Effects 0.000 description 1
150000008043 acidic salts Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000004450 alkenylene group Chemical group 0.000 description 1
150000001346 alkyl aryl ethers Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
229960001164 apremilast Drugs 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000006265 aqueous foam Substances 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 1
201000001286 autosomal recessive congenital ichthyosis 4B Diseases 0.000 description 1
229940116226 behenic acid Drugs 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000001559 benzoic acids Chemical class 0.000 description 1
WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Substances OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
230000008859 change Effects 0.000 description 1
HJWLJNBZVZDLAQ-HAQNSBGRSA-N chembl2103874 Chemical compound C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-HAQNSBGRSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
OOWQBDFWEXAXPB-UHFFFAOYSA-N chimyl alcohol Natural products CCCCCCCCCCCCCCCCOCC(O)CO OOWQBDFWEXAXPB-UHFFFAOYSA-N 0.000 description 1
229940045110 chitosan Drugs 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
229940069078 citric acid / sodium citrate Drugs 0.000 description 1
230000006003 cornification Effects 0.000 description 1
239000004148 curcumin Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
125000004431 deuterium atom Chemical group 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940031661 dimethicone 350 Drugs 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229960000735 docosanol Drugs 0.000 description 1
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
230000008406 drug-drug interaction Effects 0.000 description 1
QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
239000012183 esparto wax Substances 0.000 description 1
238000007046 ethoxylation reaction Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000013022 formulation composition Substances 0.000 description 1
208000015707 frontal fibrosing alopecia Diseases 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
229950010864 guselkumab Drugs 0.000 description 1
XMCTYDOFFXSNQJ-UHFFFAOYSA-N hexadecyl(methyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH2+]C XMCTYDOFFXSNQJ-UHFFFAOYSA-N 0.000 description 1
229940051250 hexylene glycol Drugs 0.000 description 1
102000049262 human DEFB4A Human genes 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
239000012051 hydrophobic carrier Substances 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
201000002597 ichthyosis vulgaris Diseases 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
230000005694 interleukin-22 production Effects 0.000 description 1
229940124829 interleukin-23 Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000003780 keratinization Effects 0.000 description 1
229940062711 laureth-9 Drugs 0.000 description 1
229940033355 lauric acid Drugs 0.000 description 1
229960003639 laurocapram Drugs 0.000 description 1
229940087305 limonene Drugs 0.000 description 1
235000001510 limonene Nutrition 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
150000002689 maleic acids Chemical class 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
238000007726 management method Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
XTDRLNBNAYMGCW-UHFFFAOYSA-N methyl 2-hydroxybenzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1O XTDRLNBNAYMGCW-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
229940073769 methyl oleate Drugs 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000004200 microcrystalline wax Substances 0.000 description 1
235000019808 microcrystalline wax Nutrition 0.000 description 1
229940042472 mineral oil Drugs 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
229960002969 oleic acid Drugs 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
206010030983 oral lichen planus Diseases 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012168 ouricury wax Substances 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
210000004694 pigment cell Anatomy 0.000 description 1
ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229940057847 polyethylene glycol 600 Drugs 0.000 description 1
229940094543 polyethylene glycol 900 Drugs 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000003910 polypeptide antibiotic agent Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000575 proteomic method Methods 0.000 description 1
208000026079 recessive X-linked ichthyosis Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
210000003289 regulatory T cell Anatomy 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000000518 rheometry Methods 0.000 description 1
229960004540 secukinumab Drugs 0.000 description 1
NRWMBHYHFFGEEC-UHFFFAOYSA-N selachyl alcohol Natural products CCCCCCCCC=CCCCCCCCCOCC(O)CO NRWMBHYHFFGEEC-UHFFFAOYSA-N 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
239000008279 sol Substances 0.000 description 1
235000011067 sorbitan monolaureate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
125000000542 sulfonic acid group Chemical group 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000012360 testing method Methods 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960000790 thymol Drugs 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
239000006208 topical dosage form Substances 0.000 description 1
229940025703 topical product Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012085 transcriptional profiling Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229940045136 urea Drugs 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
229940045860 white wax Drugs 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dispersion Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)

IL313248A 2021-12-03 2022-12-04 Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases IL313248A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17/541,601 US12005067B2 (en)	2020-12-04	2021-12-03	JAK inhibitor with a vitamin D analog for treatment of skin diseases
US202263365973P	2022-06-07	2022-06-07
PCT/US2022/080873 WO2023102559A1 (fr)	2021-12-03	2022-12-04	Formulations topiques de ruxolitinib avec un agent d'ajustement du ph à base d'amine organique pour le traitement de maladies de la peau

Publications (1)

Publication Number	Publication Date
IL313248A true IL313248A (en)	2024-08-01

Family

ID=88559166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL313248A IL313248A (en)	2021-12-03	2022-12-04	Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases

Country Status (9)

Country	Link
EP (1)	EP4440546A1 (fr)
JP (1)	JP2024544686A (fr)
KR (1)	KR20240139048A (fr)
CN (1)	CN118714997A (fr)
AU (1)	AU2022399851A1 (fr)
CA (1)	CA3241479A1 (fr)
IL (1)	IL313248A (fr)
MX (1)	MX2024006773A (fr)
TW (1)	TW202329975A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20260053743A1 (en) *	2024-08-26	2026-02-26	Incyte Corporation	Topical skin formulations of a pharmaceutically acceptable salt of ruxolitinib
CN119424386B (zh) *	2024-10-12	2025-07-25	深圳市泰力生物医药有限公司	含有芦可替尼的外用速溶膜及其制备方法和应用

2022
- 2022-12-04 KR KR1020247022155A patent/KR20240139048A/ko active Pending
- 2022-12-04 MX MX2024006773A patent/MX2024006773A/es unknown
- 2022-12-04 AU AU2022399851A patent/AU2022399851A1/en active Pending
- 2022-12-04 IL IL313248A patent/IL313248A/en unknown
- 2022-12-04 JP JP2024533272A patent/JP2024544686A/ja active Pending
- 2022-12-04 EP EP22847214.8A patent/EP4440546A1/fr active Pending
- 2022-12-04 CN CN202280090216.4A patent/CN118714997A/zh active Pending
- 2022-12-04 CA CA3241479A patent/CA3241479A1/fr active Pending
- 2022-12-05 TW TW111146639A patent/TW202329975A/zh unknown

Also Published As

Publication number	Publication date
CA3241479A1 (fr)	2023-06-08
JP2024544686A (ja)	2024-12-03
TW202329975A (zh)	2023-08-01
MX2024006773A (es)	2024-08-20
CN118714997A (zh)	2024-09-27
KR20240139048A (ko)	2024-09-20
AU2022399851A1 (en)	2024-06-20
EP4440546A1 (fr)	2024-10-09

Publication	Publication Date	Title
KR102914891B1 (ko)	2026-01-19	로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
US12005067B2 (en)	2024-06-11	JAK inhibitor with a vitamin D analog for treatment of skin diseases
AU2019213835B2 (en)	2024-12-19	Topical formulations comprising tofacitinib
US12551485B2 (en)	2026-02-17	Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases
EP4021456A1 (fr)	2022-07-06	Traitement d'affections cutanées à l'aide de tensioactifs anioniques à température de krafft élevée
IL313248A (en)	2024-08-01	Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases
WO2023102559A1 (fr)	2023-06-08	Formulations topiques de ruxolitinib avec un agent d'ajustement du ph à base d'amine organique pour le traitement de maladies de la peau
CN117157080A (zh)	2023-12-01	用于治疗皮肤病的含维生素d类似物的jak抑制剂
EP1980256A1 (fr)	2008-10-15	LOTION EN ÉMULSION DE TYPE HUILE DANS L'EAU CONTENANT DE LA 22-OXA-1 alpha ,25-DIHYDROXYVITAMINE D3 ET MÉTHODE DE TRAITEMENT D'UNE MALADIE CUTANÉE UTILISANT LADITE LOTION
EP3666254A2 (fr)	2020-06-17	Composition pharmaceutique contenant un (r)-n-[1-(3,5-difluoro-4-méthanesulfonylamino-phényl)-éthyl]-3-(2-propyl-6-trifluorométhyl-pyridin-3-yl)-acrylamide
US20240226068A9 (en)	2024-07-11	Topical Formulation of Disease-Modifying Antirheumatic Drug (DMARDs) for the Treatment of Rheumatoid Arthritis, Melanoma, Squamous Cell Carcinoma, Atopic Dermatitis, and Psoriasis
WO2015097513A1 (fr)	2015-07-02	Produits topiques pour aminoguanidines
EP2193798A1 (fr)	2010-06-09	Composition pharmaceutique de type émulsion de cristaux liquides contenant de la cyclosporine et procédé de traitement d'une maladie de la peau par celle-ci
US12059412B2 (en)	2024-08-13	Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof
JP5674786B2 (ja)	2015-02-25	タクロリムスを含有する水中油型クリーム状組成物